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Abstract
AIM: To examine the frequency of regular comple-
mentary and alternative therapy (CAM) use in three 
Australian cohorts of contrasting care setting and 
geography, and identify independent attitudinal and 
psychological predictors of CAM use across all cohorts. 
METHODS: A cross sectional questionnaire was 
administered to inflammatory bowel disease (IBD) 
patients in 3 separate cohorts which differed by 
geographical region and care setting. Demographics 
and frequency of regular CAM use were assessed, 
along with attitudes towards IBD medication and 
psychological parameters such as anxiety, depression, 
personality traits and quality of life (QOL), and 
compared across cohorts. Independent attitudinal and 
psychological predictors of CAM use were determined 
using binary logistic regression analysis. 
RESULTS: In 473 respondents (mean age 50.3 years, 
60.2% female) regular CAM use was reported by 
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45.4%, and did not vary between cohorts. Only 54.1% 
of users disclosed CAM use to their doctor. Independent 
predictors of CAM use which confirm those reported 
previously were: covert conventional medication 
dose reduction (P  < 0.001), seeking psychological 
treatment (P  < 0.001), adverse effects of conventional 
medication (P  = 0.043), and higher QOL (P  < 0.001). 
Newly identified predictors were CAM use by family or 
friends (P  < 0.001), dissatisfaction with patient-doctor 
communication (P  < 0.001), and lower depression 
scores (P  < 0.001). 
CONCLUSION: In addition to previously identified 
predictors of CAM use, these data show that physician 
attention to communication and the patient-doctor 
relationship is important as these factors influence CAM 
use. Patient reluctance to discuss CAM with physicians 
may promote greater reliance on social contacts to 
influence CAM decisions.  
Key words: Complementary medicine; Alternative 
therapy; Therapy; Inflammatory bowel disease; Patient-
Doctor Communication; Medication adherence
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Complementary medicine use is widespread in 
inflammatory bowel disease, and potentially deleterious 
to treatment outcomes. Whilst demographic and clinical 
predictors of complementary and alternative therapy 
(CAM) are well established, attitudinal influences are 
under explored. This study demonstrates that the 
specific aspect of patient doctor relationship most 
influencing CAM use is quality of doctor communication. 
The other newly identified predictor of CAM use is its 
use by family and friends. This finding enables valuable 
insight suggesting that in the absence of good doctor 
communication, inflammatory bowel disease patients 
seek advice from unqualified sources such as family 
and friends.
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INTRODUCTION
The use of complementary and alternative medicine 
(CAM) is widespread in inflammatory bowel disease 
(IBD), rates ranging from 31% to 74% in studies 
across Europe[1-3], Australasia[4,5], and North America[6]. 
Studies examining the efficacy and safety of these 
treatments in IBD are heterogenous and controlled 
data limited[7], thus it is difficult for physicians to 
advise patients regarding these potentially deleterious 
agents. However, the ongoing consumer demand for 
alternatives to conventional therapy means that IBD 
physicians need to be alert to CAM use, its associated 
behaviours and underlying health beliefs that may 
influence conventional IBD care. 
Approximately three quarters of CAM taking IBD 
patients do not discuss its use with their IBD physician[3,8], 
thus there is a need to identify surrogate markers or 
predictors of use that may prompt discussion about CAM 
during routine consultation.
Predictors previously established fall into demo-
graphic, clinical and attitudinal categories. Independent 
demographic predictors of CAM use include younger 
age[1,5,9], female gender[1,5,9], higher educational level[5,9], 
income and employment[5,8], and middle social class at 
birth[5]. Clinical predictors are more controversial[10,11] 
but have included Crohn’s disease[9], longer disease 
duration[12], medication type[1,13], active disease[14], 
the experience of adverse effects of conventional 
medication[2,14,15], and a concurrent diagnosis of irritable 
bowel syndrome (IBS)[16].
Some studies however, have suggested that health 
attitudes and behaviours are more important than 
demographics in influencing CAM use[15,17], and there 
has been recent enthusiasm to identify attitudinal 
and behavioural predictors as these factors are 
potentially modifiable. Data regarding such predictors 
are more limited and heterogenous but suggest 
that a need for control over disease[17], desire for a 
holistic approach[17], lack of confidence in the IBD 
physician[17], poorer therapeutic relationships[18], and 
vegetarianism[5] are associated with CAM use. CAM use 
has also been suggested as a marker of psychological 
or social distress[16].
Disparity in findings between different studies may 
relate in part to cultural differences in IBD populations, 
as suggested by an Italian study which demonstrated 
regional variations in CAM type chosen, despite similar 
rates of use across the cohorts[14]. An Australian 
diabetes study suggested an effect of health care 
setting on CAM use frequency, reporting private health 
insurance as an independent predictor of CAM use[19]. 
In IBD patients in Australia, whilst overall frequency 
and potential ethnically based differences in CAM use 
have been previously examined[4], attitudinal and 
psychological predictors of its use are unexplored, as is 
the effect of the health care setting on CAM uptake. 
MATERIALS AND METHODS
Subject selection and recruitment
IBD patients from three different care settings in 
two distinct geographical locations in Australia were 
invited to participate. This method has been reported 
previously[20].
The first cohort came from a metropolitan public 
teaching hospital based specialist IBD Service 
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at Flinders Medical Centre (FMC). This is a large, 
government funded hospital, offering secondary/tertiary 
care for a local regional population of 341000 with a 
Gastroenterology inpatient and outpatient service, and 
IBD nurses available to patients within working hours. 
The second cohort consisted of IBD patients in an 
overlapping area, receiving their care via a metropolitan 
Private Practice setting. These patients were under the 
care of one of four male general Gastroenterologists 
with extensive experience in managing IBD, without 
attachment to a specialist IBD unit, or access to IBD 
specialist nurse support.  
The third cohort consisted of IBD patients cared 
for via Royal Darwin Hospital (RDH), a public hospital 
in a very remote location in Northern Australia. When 
this study was conducted, IBD care in Darwin was 
undertaken predominantly by general practitioners 
(GPs) and general surgeons, with no specialist gastro-
enterologist residing in Darwin, and no IBD nurse. The 
nearest tertiary hospital is in Adelaide, SA, more than 
3000 kilometres away. 
Potential subjects were identified from IBD data-
bases/hospital records in each location and mailed 
a questionnaire. Reminder letters were sent to non-
responders after one and three months. 
Questionnaire content 
The opening section of the questionnaire sought demo-
graphic details including age, gender, disease type, 
indigenous, relationship and employment status as well 
as current or previous history of smoking.
In the following sections, A-D, participants answered 
questions assessing: (1) views regarding conventional 
IBD medications; (2) views regarding CAM; (3) quality 
of Life; and (4) psychological and personality traits. 
Where possible, validated instruments were used as 
described below.
IBD-specific CAM use was assessed by asking 
subjects to rate the frequency with which they use 
complementary or alternative medicine to treat IBD 
on an ordinal Likert scale. A dichotomous variable was 
then generated whereby “yes” responses encompassed 
those describing their use as “often” or “very often”, 
and “no” included responses “sometimes”, “rarely” and 
“never”.
Medication Adherence was assessed using the 
Morisky 4 item Self Report Measure of Medication 
Taking Behaviour[21,22], examining predominantly 
dose omission, and covert dose reduction (CDR), 
the tendency to take less than prescribed of IBD 
medication without prescriber awareness was assessed 
as a dichotomous variable (yes/no) based on answer 
to the question “I take less than prescribed of my IBD 
medication without telling my doctor”. This has been 
previously reported[20].
Free text responses regarding attitudes towards IBD 
medication and dose modification were encouraged.
Other non-standardised attitudinal statements 
were put to subjects, seeking their views regarding 
IBD treatment beliefs and attitudes. Some Likert 
data were collapsed into categories “yes” and “no” 
for data presentation, but analysed as ordinal data 
or continuous data using factor scores for regression 
analysis.
Anxiety and Depression were measured using the 
Hospital Anxiety and Depression Scale[23], higher scores 
indicating higher levels of anxiety or depression. Quality 
of Life was measured using the reliable and valid Short 
Inflammatory Bowel Disease Questionnaire[24]. 
The Spielberger State-Trait Personality Inventory[25-27] 
was used to assess and compare depressive symptoms, 
anxiety, anger and curiosity between cohorts in both the 
immediate (state) and long term (trait or personality 
characteristic).
Statistical analysis
Comparisons between cohort means and medians 
were performed using the Kriskal Wallis test for non-
normally distributed values, and two tailed t test or 
ANOVA for normally distributed values. Pearson’s χ 2 
or Fisher’s exact test were applied as appropriate for 
categorical data. 
Significant or trend associations at univariate level 
(P < 0.10) determined which variables were inclu-
ded in regression analyses, along with demographic 
factors.
Additional continuous variables summarising themes 
across the questionnaire were generated using principal 
component analysis for ordinal data using M Plus 
software (V5.2), for the purpose of data reduction. 
An oblique (oblimin) rotation was used of 37 of the 
55 Likert scale items assessing all aspects of IBD 
treatment. An examination of the Kaiser-Meyer Olkin 
measure of sampling adequacy suggested the sample 
was favourable (KMO = 0.618). When loadings less 
than 0.4 were excluded, the analysis yielded an 8 
factor solution. Scores for each of these 8 factors were 
normally distributed. 
Binary logistic regression was used to assess 
predictors of CAM use as a dichotomous dependent 
variable, adjusting for age, gender, employment and 
relationship status. 
A P value of < 0.05 was considered statistically 
significant. Apart from factor analysis, statistical 
calculations were performed using IBM SPSS Statistics 
for Windows, version 22, 2013 (IBM Corp). The 
statistical methods for this study were reviewed by Dr 
Reme Mountifield of Flinders Medical Centre, South 
Australia.
RESULTS
Demographic data
Response rates to the survey differed between 
cohorts, with 337/612 (55.1%) of FMC and 91/180 
(50.5%) of SA private invitees participating, compared 
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= 0.805), or vegetarianism (P = 0.256) on univariate 
analysis.
Attitudes towards CAM 
Of the 206 subjects who reported regular CAM use, 
52.5% felt that it was effective (worked “well” or 
“very well”), and 20.7% had obtained the therapy at 
consultation with an alternative practitioner rather than 
independently. The vast majority (83.3%) continued to 
use conventional IBD medications concurrently. Only 
half (54.1%) discussed their CAM treatment with their 
doctor, despite 87.6% of subjects reporting feeling 
comfortable doing so.
In contrast, of those reporting previous consultation 
with an alternative practitioner only 62.2% felt 
comfortable discussing conventional therapy with 
their alternative practitioner (P < 0.001), and 16.6% 
reported the CAM practitioner discouraged their use 
of conventional IBD medication. With regard to the 
consultation experience, 10.5% felt less intimidated 
by alternative practitioners than doctors, and 16.9% 
felt more informed about IBD by the alternative 
practitioner.
Reasons for CAM use by free text response
Of the 194/206 (94.2%) subjects who offered reasons 
for their CAM use, 33.0% reported safety concerns 
regarding conventional medications. Subjects who 
elaborated further expressed the belief that “natural” 
CAM would enable them to reduce reliance on 
“chemical” conventional therapy and dose reduce or 
cease these medications. Seeking a holistic approach 
to health in some way was cited by 32.0%, and 20.6% 
report advice from family, friends, colleagues, religious 
advisors, or the internet as their main reason for use. 
A smaller proportion (14.4%) cited lack of efficacy of 
conventional medications in treating IBD. No significant 
cohort based differences were observed. 
CAM use and treatment attitude associations-univariate 
analysis
Attitudinal and behavioural associations of CAM use on 
univariate analysis are presented in Table 3. 
with 35/100 (35%) in Darwin (P < 0.0001). Non 
respondents did not differ from respondents by 
gender (P = 0.2), but there was a trend toward non 
respondents being younger than respondents (mean 
age 43.7 vs 50.3 years, P = 0.065) Darwin subjects 
were more likely be current or previous smokers, and 
to receive a disability support pension. This population 
has been previously reported[20]. Demographic data 
are summarised in Table 1. 
Frequency, demographic and clinical associations of 
regular CAM use
Many subjects (45.4% overall) reported regular 
use of CAM, with no significant difference in usage 
frequency between cohorts (P = 0.594) (Figure 1). 
Distribution of CAM type used is presented in Table 2, 
and was not significantly different between cohorts (P 
= 0.626). The regular use of more than one CAM type 
(i.e., physical as well as homeopathic methods) was 
reported by 64.5% of subjects.
Rates of CAM use were higher amongst younger 
(46.69 vs 53.41 years, P < 0.001), female (52.0% vs 
35.5%, P < 0.001), and permanently employed (51.1% 
vs 37.4%, P = 0.004) subjects. However, CAM usage 
did not differ by disease type (P = 0.394), conventional 
medication pill burden (P = 0.784), smoking status (P 
Table 1  Demographics in contrasting inflammatory bowel 
disease cohorts
FMC 
(n  = 337)
Private 
(n  = 91)
Darwin 
(n  = 35)
P  value
Mean age respondents (yr) 50.3 52.2 48.4 0.35
Mean age non respondents 
(yr)
43.0 48.1 39.9 0.20
Female respondents 60.2% 60.4%    60% 0.99
Female non respondents 55.7% 52.4% 40.7% 0.07
Crohn’s disease 55.2% 57.1% 48.6% 0.70
Indigenous subjects   0.9%   1.1%   2.9% 0.37
Current smokers 11.1% 13.6% 17.1% 0.09
Previous smokers 25.8% 25.0% 42.9% 0.09
Receiving disability support 
pension
  1.8%   1.1%   5.7%   0.006
Employed 58.7% 56.7% 62.9% 0.19
Currently partnered 92.2 95.3 93.3 0.61
Table 2  Distribution of complementary and alternative therapy 
types reported by inflammatory bowel disease subjects 
Primary (first mentioned) CAM type Percentage of total CAM 
reported overall
Herbal products (e.g., slippery elm, 
aloe vera juice, olive oil extract, green 
lipped mussel oil, other herbs)
30.50%
Probiotics 22.60%
Fish oil 12.10%
Chinese medicine 10.50%
Acupuncture, massage, magnetism 10.50%
Other (prayer, meditation, exercise, 
dietary supplements, hypnotherapy)
13.70%
CAM: Complementary and alternative therapy.
47%
46%
45%
44%
43%
42%
41%
39%
38%
37%
36%
FMC              Private             Darwin
P  = 0.626
Figure 1  Proportion of subjects in each cohort reporting regular com­
plementary medicine use.
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Of all subjects including CAM users and non-users, 
57.3% reported family or friends using CAM for any 
health purpose. Those with CAM-using contacts was 
more likely to use it themselves for IBD (59.9% vs 
40.1%, P = 0.004), free text responses suggesting 
that type of CAM chosen was influenced by social 
contacts.
The 54.9% of subjects reporting adverse effects 
of conventional medications were more likely to 
use CAM (P = 0.025), as were the 26.9% reporting 
regular self-initiated dose reduction of medication (P < 
0.001). Lack of doctor communication satisfaction was 
reported by only a small proportion of patients (2.4%) 
but was associated with CAM use, as was seeking of 
psychological or psychiatric treatment (P < 0.001) 
when analysed as individual items.
Analysis of HADS, QOL and Spielberger mean 
scores suggested that increased anxiety, higher quality 
of life and lower depression scores were associated 
with increased CAM use, whilst personality type did not 
influence rate of use (Table 4). 
Independent predictors of regular CAM use 
After adjustment for age, gender, disease type and 
employment level, attitudinal and psychological 
predictors of regular CAM use using binary logistic 
regression analysis are shown in Table 5. This model 
explained a significant proportion of variance in low 
adherence rates (adjusted pseudo R squared 0.217, 
goodness of fit Hosmer Lemeshow P = 0.161).
After adjustment for demographics a trend was 
observed toward higher CAM usage amongst non-
smokers (OR = 1.299, 95%CI: 0.993-1.698, P = 
0.056).
Covert dose reduction, lower depression scores 
and subjects’ propensity to seek psychological help 
predicted CAM use, the latter factor analysis generated 
variable encompassing use of antidepressants, and 
consultations with counsellors, psychologists or 
psychiatrists (Table 5). Similarly, the factor analysis 
generated variable assessing dissatisfaction with 
doctor communication was an independent predictor 
of CAM use, and included satisfaction level with 
doctor relationship, doctor communication style, 
level of comfort in asking questions of doctor, and 
comprehension of information provided during 
consultation.
DISCUSSION
This study demonstrates the high frequency of CAM 
use amongst IBD patients in Australia, and suggests 
that such use occurs independently of health care 
setting and geography. Newly identified attitudinal 
and psychological risk factors include dissatisfaction 
with patient-doctor communication, CAM use by social 
contacts and lower depression scores. We confirm both 
the known demographic risk factors for CAM use and 
known behavioural associations such as covert dose 
reduction, psychotherapeutic support seeking, and 
adverse effects of conventional medications. 
The frequency of regular CAM use was slightly 
Table 3  Attitudinal and behavioural associations of regular 
complementary and alternative therapy use - univariate 
analysis  n  (%)
Regular CAM use P  value
No Yes
Deliberate dose reduction No 197 (61.4) 124 (38.6) < 0.001
Yes   46 (38.7)   73 (61.3)
Family or friends use 
alternative treatments
No   88 (55.0)   72 (45.0)    0.004
Yes   85 (40.1) 127 (59.9)
Experienced adverse effects 
conventional IBD meds
No   89 (59.7)   60 (40.3)    0.025
Yes 129 (48.3) 138 (51.7)
Satisfied with 
communication with IBD 
doctor
No   1 (9.1)   10 (90.9)    0.002
Yes 246 (55.7) 196 (44.3)
Previous psychological 
counselling
No 197 (61.6) 123 (38.4) < 0.001
Yes   49 (38.0)   80 (62.0)
CAM: Complementary and alternative therapy; IBD: Inflammatory bowel 
disease.
Table 4  Anxiety, depression, quality of life and personality 
traits in users vs non users of cam in inflammatory bowel 
disease - univariate analysis
Regular 
CAM use
Mean SD SE 2 tailed 
P  value
Anxiety (HADS) No 8.3312 3.50750 0.09032    0.017
Yes 8.6365 3.18002 0.08969
Depression 
(HADS)
No 6.8774 2.85105 0.07354    0.002
Yes 6.5556 2.67318 0.07540
SIBDQ No 56.0152 9.71282 0.25137 < 0.001
Yes 58.1210 9.57504 0.27126
Trait anxiety No 21.0042 2.53088 0.06539    0.341
Yes 21.0957 2.48538 0.07019
Trait curiosity No 25.831 6.13307 0.15836    0.916
Yes 25.8549 5.71720 0.16158
Trait anger No 11.3837 3.93971 0.10169    0.385
Yes 11.5097 3.60996 0.10202
Trait depression No 18.9960 3.59568 0.09293    0.744
Yes 19.0385 3.12376 0.08818
Table 5  Independent attitudinal predictors of regular 
complementary and alternative therapy use in inflammatory 
bowel disease - logistic regression analysis 
Odds ratio 95%CI P  value
Covert dose reduction 2.588 2.135-3.138 < 0.001
Seeking psychological treatment 1.888 1.563-2.280 < 0.001
Family and friends are regular 
CAM users
1.710 1.434-2.044 < 0.001
Dissatisfied with doctor 
communication
1.561 1.304-1.869 < 0.001
Adverse effects conventional 
medications
1.208 1.006-1.467    0.043
Depression (HADS) 0.910 0.878-0.943 < 0.001
Quality of life (SIBDQ) 1.022 1.011-1.032 < 0.001
CAM: Complementary and alternative therapy.
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higher in our study population (45.4%) than reported 
previously in Australia[4], but within the range reported 
internationally[1,4,28]. Similarly to the Italian study 
assessing regional variation in CAM use[14], we found 
no difference in overall rates of CAM use between 
cohorts, but in contrast did not find regional variation 
in the type of CAM chosen either. Some variation 
in choice of CAM type is seen between populations 
globally, our predominantly Caucasian cohorts being 
comparable with New Zealand IBD subjects amongst 
whom herbs and vitamins were most commonly 
used[5]. Interestingly nearly two thirds of subjects used 
more than one type of CAM, however, overlapping 
physical and homeopathic methods and rendering 
further analysis by individual CAM type difficult. 
Although the patient doctor relationship is known to 
affect CAM use[29], the more specific aspect of doctor 
communication quality as a predictor has not been 
previously reported. Subjects who were dissatisfied 
with the style of communication from their doctor, did 
not feel information was presented in a comprehensible 
way, or felt that the consultation environment did not 
encourage patient questions, were significantly more 
likely to use CAM after adjustment for other factors. 
A Canadian study found that the wish for a more 
active role in treatment decisions was associated with 
CAM use[17], and the desire for more information from 
doctors was predictive of use in an Italian cohort[30]. 
The significant influence of CAM use behaviours 
amongst social contacts on CAM uptake decisions in 
IBD individuals has also not been previously reported. 
In our study this was adjusted for age, gender, and 
employment level but not for other demographics 
which may be common across family members and 
confound the association. Such influence would not be 
surprising, however, given the effect of marital status, 
for example, on other medication taking behaviours 
such as adherence to conventional therapy in IBD[31]. 
A study of healthy adolescents found that social 
contacts exert significant influence over the decision 
to use CAM[32], and further work to investigate this 
in IBD populations is warranted, especially given 
the escalating influence of social media on everyday 
decision making. 
Previously reported predictors including CDR 
of conventional medications, adverse effects of 
medications and increased QOL were confirmed in this 
study. Free text responses strongly suggested that 
IBD CAM users tend to reduce rather than omit doses 
of conventional medications on the assumption that 
CAM use will provide a “medication sparing” effect, the 
aim being to minimise adverse effects of conventional 
medications. This newly described phenomenon is the 
subject of a separate publication[20], which suggests 
that similar underlying health beliefs and desires 
drive both CAM uptake and CDR behaviour. Although 
abundant free text data from this study support 
this hypothesis, formal path analysis has yet to be 
undertaken to confirm the direction of causality in the 
association between CAM use and CDR.
Those subjects seeking psychological input such 
as counselling, psychologist or psychiatrist review, or 
antidepressant medication were significantly more 
likely to use CAM in this study, and this has been 
previously demonstrated in two European studies[1,13]. 
Free text responses suggested that CAM was not 
being prescribed by the psychological care provider, 
but rather both behaviours were the result of a desire 
for a holistic health approach with active ways of 
coping, and this has been previously reported[13]. 
This may be supported by our new finding that lower 
depression scores were associated with CAM use, 
perhaps indicating the presence of successfully treated 
depression in this population who may be more 
receptive to psychology.
Gastroenterologist awareness of CAM use was 
similar in our study to the 46% seen in a French web 
based study of IBD patients[10], but greater than that 
found elsewhere[3,8,33]. This communication gap may 
be contributed to by both consultation participants, 
a study examining CAM use in IBD patients from 
the physician perspective finding that only 8% of 
IBD physicians had initiated CAM conversations 
themselves, and only around 50% were comfortable 
discussing CAM with their patients[33]. 
The confirmation of previously reported demographic 
and attitudinal CAM predictors suggests that our study 
population is similar to others, and thus the results 
generalizable to some extent. The limitations of this 
study include the small amount of clinical information 
obtainable from subjects by self-report, including 
disease activity and response to conventional therapy. 
Additionally, comparisons between cohorts were 
hampered by the uneven group sizes and response 
rates across different treatment settings. Statistical 
analysis differentiating by CAM type is likely to be 
important but was not feasible in this study as most 
subjects (64.5%) reported using more than one 
therapy type. Also, the definition of CAM is not uniform 
across studies and in this case was defined as what 
subjects felt was outside of “conventional” therapy.
CAM use is highly prevalent and appears inde-
pendent of care setting and geography in IBD, and its 
importance to patients is often under-recognised by 
physicians. The quality of patient doctor communication 
is a key determinant, and failure to actively address 
CAM use in consultation may promote patient “default” 
to other advice sources such as family, friends and 
other social contacts, which ultimately undermines the 
patient doctor relationship.
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adherence to conventional therapy. 
Applications 
IBD physicians need to attend more closely than ever to clear communication 
with patients regarding the risks and benefits of conventional therapy, and 
enquire about CAM use to better understand the patient’s context. Patient 
understanding of disease and therapy should be routinely assessed by 
physicians in order to correct misperceptions introduced by social contacts, 
alternative practitioners and the internet that may undermine successful IBD 
treatment.
Peer-review
This well presented study makes an important contribution to the literature as it 
highlights the broader context of individuals with IBD, reporting new behavioural 
predictors of complementary medicine uptake in this population which warrant 
attention during consultation.
REFERENCES
1 Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, 
Kristof T, Nagy F, Salamon A, Demeter P, Miheller P, Szamosi T, 
Banai J, Papp M, Bene L, Kovacs A, Racz I, Lakatos L. Association 
of adherence to therapy and complementary and alternative medicine 
use with demographic factors and disease phenotype in patients 
with inflammatory bowel disease. J Crohns Colitis 2010; 4: 283­290 
[PMID: 21122517 DOI: 10.1016/j.crohns.2009.11.011]
2 Opheim R, Bernklev T, Fagermoen MS, Cvancarova M, Moum 
B. Use of complementary and alternative medicine in patients 
with inflammatory bowel disease: results of a cross-sectional study 
in Norway. Scand J Gastroenterol 2012; 47: 1436­1447 [PMID: 
23003678 DOI: 10.3109/00365521.2012.725092]
3 Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus 
B. Use of complementary and alternative medicine in Germany 
­ a survey of patients with inflammatory bowel disease. BMC 
Complement Altern Med 2006; 6: 19 [PMID: 16716218 DOI: 
10.1186/1472­6882­6­19]
4 Leong RW, Lawrance IC, Ching JY, Cheung CM, Fung SS, Ho 
JN, Philpott J, Wallace AR, Sung JJ. Knowledge, quality of life, and 
use of complementary and alternative medicine and therapies in 
inflammatory bowel disease: a comparison of Chinese and Caucasian 
patients. Dig Dis Sci 2004; 49: 1672­1676 [PMID: 15573925 DOI: 
10.1023/B:DDAS.0000043384.26092.f4]
5 Koning M, Ailabouni R, Gearry RB, Frampton CM, Barclay ML. 
Use and predictors of oral complementary and alternative medicine 
by patients with inflammatory bowel disease: a population­based, 
case­control study. Inflamm Bowel Dis 2013; 19: 767­778 [PMID: 
23429459 DOI: 10.1097/MIB.0b013e31827f27c8]
6 Rawsthorne P, Clara I, Graff LA, Bernstein KI, Carr R, Walker 
JR, Ediger J, Rogala L, Miller N, Bernstein CN. The Manitoba 
Inflammatory Bowel Disease Cohort Study: a prospective 
longitudinal evaluation of the use of complementary and alternative 
medicine services and products. Gut 2012; 61: 521­527 [PMID: 
21836028 DOI: 10.1136/gutjnl­2011­300219]
7 Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic 
review: the efficacy of herbal therapy in inflammatory bowel disease. 
Aliment Pharmacol Ther 2013; 38: 854­863 [PMID: 23981095 DOI: 
10.1111/apt.12464]
8 Park DI, Cha JM, Kim HS, Park HJ, Shin JE, Hong SN, Hong 
SS, Kim WJ. Predictive factors of complementary and alternative 
medicine use for patients with inflammatory bowel disease in Korea. 
Complement Ther Med 2014; 22: 87­93 [PMID: 24559822 DOI: 
10.1016/j.ctim.2013.12.001]
9 Opheim R, Hoivik ML, Solberg IC, Moum B. Complementary and 
alternative medicine in patients with inflammatory bowel disease: 
the results of a population­based inception cohort study (IBSEN). J 
Crohns Colitis 2012; 6: 345­353 [PMID: 22405172 DOI: 10.1016/
j.crohns.2011.09.007]
10 Abitbol V, Lahmek P, Buisson A, Olympie A, Poupardin C, 
Chaussade S, Lesgourgues B, Nahon S. Impact of complementary 
and alternative medicine on the quality of life in inflammatory bowel 
disease: results from a French national survey. Eur J Gastroenterol 
Hepatol 2014; 26: 288­294 [PMID: 24407360 DOI: 10.1097/
MEG.0000000000000040]
11 Agathou CL, Beales IL. Factors associated with the use of 
probiotics in patients with inflammatory bowel disease. F1000Res 
2013; 2: 69 [PMID: 24555045]
12 Fernández A, Barreiro­de Acosta M, Vallejo N, Iglesias M, 
Carmona A, González­Portela C, Lorenzo A, Domínguez­Muñoz 
JE. Complementary and alternative medicine in inflammatory bowel 
disease patients: frequency and risk factors. Dig Liver Dis 2012; 44: 
904­908 [PMID: 22795615 DOI: 10.1016/j.dld.2012.06.008]
13 Langhorst J, Anthonisen IB, Steder­Neukamm U, Lüdtke R, Spahn 
G, Michalsen A, Dobos GJ. Amount of systemic steroid medication 
is a strong predictor for the use of complementary and alternative 
medicine in patients with inflammatory bowel disease: results from 
a German national survey. Inflamm Bowel Dis 2005; 11: 287­295 
[PMID: 15735435 DOI: 10.1097/01.MIB.0000160771.71328.6c]
14 Bertomoro P, Renna S, Cottone M, Riegler G, Bossa F, Giglio L, 
Pastorelli L, Papi C, Castiglione F, Angelucci E, Pica R, Di Paolo 
MC, D’Incà R. Regional variations in the use of complementary 
and alternative medicines (CAM) for inflammatory bowel disease 
patients in Italy: an IG­IBD study. J Crohns Colitis 2010; 4: 291­300 
[PMID: 21122518 DOI: 10.1016/j.crohns.2009.12.009]
15 Quattropani C, Ausfeld B, Straumann A, Heer P, Seibold F. 
Complementary alternative medicine in patients with inflammatory 
bowel disease: use and attitudes. Scand J Gastroenterol 2003; 38: 
277­282 [PMID: 12737442]
16 Langmead L, Chitnis M, Rampton DS. Use of complementary 
therapies by patients with IBD may indicate psychosocial distress. 
Inflamm Bowel Dis 2002; 8: 174­179 [PMID: 11979137 DOI: 10.10
97/00054725­200205000­00003]
17 Li FX, Verhoef MJ, Best A, Otley A, Hilsden RJ. Why patients 
with inflammatory bowel disease use or do not use complementary 
and alternative medicine: a Canadian national survey. Can J 
Gastroenterol 2005; 19: 567­573 [PMID: 16151549]
18 Richardson MA, Mâsse LC, Nanny K, Sanders C. Discrepant views 
of oncologists and cancer patients on complementary/alternative 
medicine. Support Care Cancer 2004; 12: 797­804 [PMID: 
15378417]
19 Lui CW, Dower J, Donald M, Coll JR. Patterns and Determinants 
of Complementary and Alternative Medicine Practitioner Use 
among Adults with Diabetes in Queensland, Australia. Evid Based 
Complement Alternat Med 2012; 2012: 659419 [PMID: 22919416 
DOI: 10.1155/2012/659419]
20 Morisky DE, Green LW, Levine DM. Concurrent and predictive 
validity of a self­reported measure of medication adherence. Med 
Care 1986; 24: 67­74 [PMID: 3945130 DOI: 10.1097/00005650­19
8601000­00007]
21 Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity 
of a medication adherence measure in an outpatient setting. J Clin 
Hypertens (Greenwich) 2008; 10: 348­354 [PMID: 18453793 DOI: 
10.1111/j.1751­7176.2008.07572.x]
 COMMENTS
Mountifield R et al . Complementary medicine use in IBD
3670 March 28, 2015|Volume 21|Issue 12|WJG|www.wjgnet.com
22 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983; 67: 361­370 [PMID: 6880820 DOI: 
10.1111/j.1600­0447.1983.tb09716.x]
23 Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel 
Disease Questionnaire: a quality of life instrument for community 
physicians managing inflammatory bowel disease. CCRPT 
Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J 
Gastroenterol 1996; 91: 1571­1578 [PMID: 8759664]
24 Spielberger CD. Cross­cultural assessment of emotional states and 
personality traits. Europ Psychol 2006; 11: 297­303 [DOI: 10.1027/1
016­9040.11.4.297]
25 Spielberger C. Manual for the State­Trait Anxiety Inventory. Palo 
Alto, CA: Consulting Psychologists Press, 1970
26 Forsberg C, Björvell H. Swedish population norms for the GHRI, 
HI and STAI­state. Qual Life Res 1993; 2: 349­356 [PMID: 
8136800]
27 Mountifield R, Andrews JM, Mikocka-Walus A, Bampton P. 
Covert dose reduction is a distinct type of medication non­adherence 
observed across all care settings in inflammatory bowel disease. J 
Crohns Colitis 2014; 8: 1723­1729 [PMID: 25263934 DOI: 10.1016/
j.crohns.2014.08.013]
28 Weizman AV, Ahn E, Thanabalan R, Leung W, Croitoru K, 
Silverberg MS, Steinhart AH, Nguyen GC. Characterisation of 
complementary and alternative medicine use and its impact on 
medication adherence in inflammatory bowel disease. Aliment 
Pharmacol Ther 2012; 35: 342­349 [PMID: 22176478 DOI: 
10.1111/j.1365­2036.2011.04956.x]
29 Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, 
Bouché O, Thiéfin G, Cadiot G. Complementary and alternative 
medicine use by patients with inflammatory bowel disease: results 
from a postal survey. Gastroenterol Clin Biol 2006; 30: 14­23 [PMID: 
16514377 DOI: 10.1016/S0399­8320(06)73072­X]
30 D’Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di 
Leo V, Buda A, Sturniolo GC. Use of alternative and complementary 
therapies by inflammatory bowel disease patients in an Italian 
tertiary referral centre. Dig Liver Dis 2007; 39: 524­529 [PMID: 
17433794]
31 Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, 
Kalantzis N. How adherent to treatment with azathioprine are 
patients with Crohn’s disease in long­term remission? Inflamm 
Bowel Dis 2007; 13: 446­450 [PMID: 17206674 DOI: 10.1002/
ibd.20041]
32 Patterson C, Arthur H, Noesgaard C, Caldwell P, Vohra J, Francoeur 
C, Swinton M. Exploring adolescent complementary/alternative 
medicine (CAM) use in Canada. J Interprof Care 2008; 22: 45­55 
[PMID: 18202985 DOI: 10.1080/13561820701795374]
33 Gallinger Z, Bressler B, Devlin SM, Plamondon S, Nguyen GC. A 
survey of perceptions and practices of complementary alternative 
medicine among Canadian gastroenterologists. Can J Gastroenterol 
Hepatol 2014; 28: 45­49 [PMID: 24212913]
P- Reviewer: Iwasaki Y, Jani K, Shimizu Y, Tasci I    S- Editor: Qi Y 
L- Editor: A    E- Editor: Wang CH 
Mountifield R et al . Complementary medicine use in IBD
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
1  2
